Literature DB >> 27430345

RNA interference against TRIM29 inhibits migration and invasion of colorectal cancer cells.

Weihong Xu1, Bin Xu1, Yiting Yao1, Xiaoling Yu1, Hua Cao1, Jun Zhang2, Jie Liu2, Huiming Sheng1.   

Abstract

Colorectal cancer (CRC) is one of the most common malignancies worldwide. Tripartite motif-containing 29 (TRIM29) is a member of TRIM proteins family, which plays diverse physiological and pathological roles in humans. Recent studies found that TRIM29 expressed highly in CRC and promoted cell growth in vitro. However, its function in the metastasis of CRC has not been studied. In the present study, we confirmed the previous report that TRIM29 was upregulated in CRC tissues and high levels of TRIM29 expression were associated with poor overall survival of patients. Moreover, TRIM29 knockdown significantly reduced cancer cell proliferation via notably inducing cell cycle arrest and cell apoptosis. Silencing of TRIM29 significantly inhibited the migration and invasion ability of CRC cells. The protein levels of apoptosis‑, migration‑ and invasion‑related proteins were also changed after TRIM29 knockdown. Furthermore, phosphorylation levels of JAK2 and STAT3 were clearly reduced in TRIM29 knockdown cells, indicating a possible mechanism underlying its effects on colorectal carcinogenesis. Collectively, TRIM29 may exert oncogenic effects in CRC cells via regulating JAK2/STAT3 signaling.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27430345     DOI: 10.3892/or.2016.4941

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  16 in total

1.  iTRAQ-based quantitative proteomic analysis of differentially expressed proteins in chemoresistant nasopharyngeal carcinoma.

Authors:  Kun Wang; Zhen Chen; Lu Long; Ya Tao; Qiong Wu; Manlin Xiang; Yunlai Liang; Xulin Xie; Yuan Jiang; Zhiqiang Xiao; Yahui Yan; Shiyang Qiu; Bin Yi
Journal:  Cancer Biol Ther       Date:  2018-08-01       Impact factor: 4.742

2.  LncRNA HOXA11-AS accumulation-induced microRNA-761 downregulation regulates cell growth by targeting TRIM29 in papillary thyroid cancer.

Authors:  Xiangdang Yin; Jian Zhang; Chaojun Li; Zhe Zhang; Tong Jin; Liyou Song; Rui Zhang; Wei Wang; Youmao Tao; Xiaochun Wang
Journal:  Am J Transl Res       Date:  2019-11-15       Impact factor: 4.060

3.  Clinical significance of TRIM29 expression in patients with gastric cancer.

Authors:  Javad Farhadi; Jamshid Mehrzad; Hassan Mehrad-Majd; Alireza Motavalizadehkakhky
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2022

Review 4.  TRIM family contribute to tumorigenesis, cancer development, and drug resistance.

Authors:  Ning Huang; Xiaolin Sun; Peng Li; Xin Liu; Xuemei Zhang; Qian Chen; Hong Xin
Journal:  Exp Hematol Oncol       Date:  2022-10-19

5.  TRIM14 promotes colorectal cancer cell migration and invasion through the SPHK1/STAT3 pathway.

Authors:  Zhonghai Jin; Hongguang Li; Xiaofei Hong; Guangrong Ying; Xiaofeng Lu; Lilei Zhuang; Shenbao Wu
Journal:  Cancer Cell Int       Date:  2018-12-11       Impact factor: 5.722

6.  TRIM52 promotes colorectal cancer cell proliferation through the STAT3 signaling.

Authors:  Shengli Pan; Yingying Deng; Jun Fu; Yuhao Zhang; Zhijin Zhang; Xiaokun Ru; Xianju Qin
Journal:  Cancer Cell Int       Date:  2019-03-14       Impact factor: 5.722

7.  TRIM14 promotes cell proliferation and inhibits apoptosis by suppressing PTEN in colorectal cancer.

Authors:  Weidong Shen; Zhonghai Jin; Xiuping Tong; Haiying Wang; Lilei Zhuang; Xiaofeng Lu; Shenbao Wu
Journal:  Cancer Manag Res       Date:  2019-06-24       Impact factor: 3.989

Review 8.  E3 Ubiquitin Ligase TRIM Proteins, Cell Cycle and Mitosis.

Authors:  Santina Venuto; Giuseppe Merla
Journal:  Cells       Date:  2019-05-27       Impact factor: 6.600

9.  TRIM27 functions as an oncogene by activating epithelial-mesenchymal transition and p-AKT in colorectal cancer.

Authors:  Yue Zhang; Yifei Feng; Dongjian Ji; Qingyuan Wang; Wenwei Qian; Shijia Wang; Zhiyuan Zhang; Bing Ji; Chuan Zhang; Yueming Sun; Zan Fu
Journal:  Int J Oncol       Date:  2018-05-16       Impact factor: 5.650

10.  ATDC mediates a TP63-regulated basal cancer invasive program.

Authors:  Phillip L Palmbos; Yin Wang; Armand Bankhead Iii; Alan J Kelleher; Lidong Wang; Huibin Yang; McKenzie L Ahmet; Erica R Gumkowski; Samuel D Welling; Brian Magnuson; Jacob Leflein; Guadalupe Lorenzatti Hiles; Ethan V Abel; Michele L Dziubinski; Sumithra Urs; Mark L Day; Mats E Ljungman; Diane M Simeone
Journal:  Oncogene       Date:  2019-01-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.